Form 4: Director Lewis T. Williams Granted Equity in Protagonist Therapeutics

Protagonist Therapeutics director Lewis T. Williams received a grant of 2,695 restricted stock units and options for 3,762 shares on January 2, 2026.

Summary

• Lewis T. Williams, a Director of Protagonist Therapeutics, Inc. (PTGX), was granted 2,695 restricted stock units (RSUs) on January 2, 2026.
• These RSUs are payable solely in common stock and will vest in full on January 15, 2027, contingent upon Mr. Williams' continued service to the Issuer.
• Additionally, Mr. Williams was granted stock options for 3,762 shares of common stock with an exercise price of $87.18 per share on January 2, 2026.
• The stock options will vest in 12 equal monthly installments following January 2, 2026, also subject to Mr. Williams' continued service through each applicable vesting date.
• Following these transactions, Mr. Williams beneficially owns 7,825 shares of common stock directly and 3,762 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The filing reports an equity grant to a director, which is a standard compensation practice aligning management interests with shareholders. It's a neutral event for the company's operational performance but positive for director retention and alignment.

Positives

• The grant of restricted stock units and stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term performance.
• The equity grants serve as a retention mechanism, contingent on the director's continued service to the company.

Risks

• The vesting of both the restricted stock units and stock options is subject to the reporting person's continued service to the Issuer through the respective vesting dates, meaning the equity could be forfeited if service ceases prematurely.

Future Outlook

The future outlook for the reported equity grants is tied to the continued service of Lewis T. Williams to Protagonist Therapeutics, Inc. The restricted stock units are set to vest in full on January 15, 2027, and the stock options will vest in 12 equal monthly installments following January 2, 2026, both subject to this condition.

Industry Context

This filing is a standard disclosure of an insider equity grant, a common practice in the biotechnology and pharmaceutical industry to compensate and incentivize directors and executives. Such grants are typically part of a broader compensation strategy aimed at aligning management interests with long-term shareholder value creation.

Stakeholder Impact

• Shareholders: The equity grants could lead to minor dilution upon vesting and exercise, but they also serve to align the director's long-term interests with shareholder value creation.
• Employees: This specific filing pertains to a director's compensation and does not directly impact the broader employee base.

Next Steps

• Continued service of Lewis T. Williams to Protagonist Therapeutics, Inc. to meet vesting conditions for RSUs and stock options.
• Vesting of stock options in 12 equal monthly installments following January 2, 2026.
• Full vesting of restricted stock units on January 15, 2027.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a director as part of their compensation. While it aligns the director's interests with shareholders, it does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals.

Keywords

Protagonist Therapeutics, PTGX, Lewis T. Williams, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Grant, Director Compensation